Braveheart Bio Inc BRVE

$19.62 -0.88 (-4.29%)

Valuation

Market cap
1,763,250,000
Revenue TTM
$0
Net income TTM
$-66,050,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
536,600
Avg volume
488,570
Day's range
$19.18 – $20.41
Shares out
89,870,000
Stochastic %K
57%
Beta
—
Analysts
Strong Buy
Price target
$45.50

Price

Company profile

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Fr...

Show more

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 707 6312
Website
https://www.braveheart.bio
Address
One Letterman Drive, Building A Suite A4-300, San Francisco, United States

Latest news

No headlines yet.